Showing results (41-50 of 73) with videos related to

Sort By:
Pageof 8
Oncotarget|September 17, 2016
Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOXYasuhiro Kaga, Yu Sunakawa, Yutaro Kubota, et al.
Anticancer Research|April 30, 2022
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab RegimenHiroaki Tanioka, Ken Shimada, Akihito Tsuji, et al.
Molecular Cancer Therapeutics|March 18, 2016
TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based ChemotherapySatoshi Matsusaka, Wu Zhang, Shu Cao, et al.
Oncotarget|July 26, 2018
Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2017
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placeboMakoto Ueno, Chung Pin Li, Masafumi Ikeda, et al.
BMC Cancer|March 28, 2013
Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancerMegumi Ishiguro, Kenjiro Kotake, Genichi Nishimura, et al.
Targeted Oncology|October 25, 2017
CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal CancerYu Sunakawa, Akihito Tsuji, Tadamichi Denda, et al.
Oncotarget|May 4, 2018
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, et al.
Anticancer Research|April 30, 2022
Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II TrialKeisho Chin, Daisuke Takahari, Ryohei Kawabata, et al.
The Oncologist|February 28, 2026
Real-world outcomes of encorafenib, cetuximab ± binimetinib for BRAF‑mutated metastatic colorectal cancer: The BEETS (JACCRO CC‑18) studyDaisuke Kotani, Eisuke Inoue, Tadamichi Denda, et al.
Pageof 8